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Clozapine-carboxylic acid plasticized co-amorphous dispersions: 
Preparation, characterization and solution stability evaluation
This study addressed the possibility of forming of co-amor-
phous systems between clozapine (CZ) and various carbox-
ylic acid plasticizers (CAPs). The aim was to improve the 
solubility and oral bioavailability of clozapine. Co-amor-
phous dispersions were prepared using modifi ed solvent 
evaporation methodology at drug/plasticizer stoichiometric 
ratios of 1:1, 1:1.5 and 1:2. Solid state characterization was 
performed using diff erential scanning calorimetry, X-ray 
diff raction and infra red spectroscopy. Highly soluble homo-
geneous co-amorphous dispersions were formed between 
clozapine and CAPs via hydrogen bonding. The co-amor-
phous dispersions formed with tartaric acid (1:2) showed the 
highest dissolution percentage (> 95 % in 20 minutes) com-
pared to pure crystalline CZ (56 %). Highly stable solutions 
were obtained from co-amorphous CZ-citric and CZ-tartaric 
acid at 1:1.5 molar ratio. The prepared dispersions suggest 
the possibility of peroral or sublingual administration of 
highly soluble clozapine at a reduced dose with the great 
chance to bypass the fi rst pass metabolism.
Keywords: clozapine, carboxylic acids, co-amorphous sys-
tems, plasticizer
Clozapine is one of the potent antipsychotic drugs that have been used in the treat-
ment of schizophrenia (1). The drug has a biological half-life of 6.5 ± 1.5 h and undergoes 
extreme fi rst-pass metabolism a er oral administration; its bioavailability ranges from 
27–50 % of the ingested dose (2, 3). Clozapine has low water solubility, being soluble only 
in acidic solutions, and hence improvement of its water solubility will enable reduction of 
oral dosing and help in overcoming the side eff ects, which include weight gain, induced 
fever and agranulocytosis (4). Bypassing the fi rst-pass metabolism can be achieved by 
using oral dosage forms such as buccal fast dissolving or sublingual tablets (5). Various 
a empts were made to improve its bioavailability by using co-amorphous lipid nanopar-
ticles for oral administration (6) or to formulate clozapine into sustained release formula-
tions using cross-linked chitosan microparticles (7). Co-amorphous dispersions and co-
AHMED MAHMOUD ABDELHALEEM ALI1,2*
ADEL AHMED ALI1
IBRAHIM ABDULLAH MAGHRABI2
1 Department of Pharmaceutics
Faculty of Pharmacy
Beni Suef University, Egypt
2 Department of Clinical Pharmacy
Faculty of Pharmacy
Taif University
Kingdom Saudi Arabia
Accepted November 3, 2014
* Correspondence; e-mail: ahmed.abdelhalem@pharm.bsu.edu.eg, ahmed.mahmoud3@yahoo.com
134
A. M. Abdelhaleem Ali et al.: Clozapine-carboxylic acid plasticized co-amorphous dispersions: Preparation, characterization and 
solution stability evaluation, Acta Pharm. 65 (2015) 133–146.
 
crystals are recent and highly eff ective approaches used to improve water solubility and 
bioavailability of poorly soluble crystalline drugs (8). Although these two systems are dif-
ferent in shape, they are commonly known as multi-component dispersions composed of 
an active ingredient with one or more neutral molecules known as co-formers (9, 10). How-
ever, co-crystallization o en needs sophisticated methods for preparation and quantifi ca-
tion, in addition to physical instability and possible formation of polymorphs and hy-
drates. Amorphous solids are non-crystalline materials, in which the arrangement of the 
component atoms does not have a long-range order. They are also considered suitable and 
easy alternatives to co-crystals and provide higher dissolution rates (11). Co-amorphous 
dispersions can be prepared from solutions of crystalline drugs, especially when rapid 
co-precipitation is pursued using carboxylic acids as plasticizing agents (12, 13). Stable co-
amorphous systems have been prepared from low solubility drugs and small molecular 
mass amino acids (14) or neutral molecules capable of forming strong H-bonding such as 
saccharin (15) or nicotinamide (16). Although numerous successful plasticized formula-
tions have been prepared using carboxylic acids (17–20), plasticized co-amorphous disper-
sions prepared from crystalline drugs with polycarboxylic acids are rare. Moreover, no 
studies have addressed the use of carboxylic acid plasticizers (CAPs) in amorphization of 
solid crystalline drugs by employing solvent evaporation under vacuum as the method of 
preparation. Therefore, in this research, preparation of stable clozapine co-amorphous 
dispersions by evaporation under vacuum was addressed in an a empt to enhance the 
drug water solubility, bioavailability and to enable reduced dosing.
EXPERIMENTAL
Materials
Clozapine was obtained as a free sample from the Egyptian Pharmaceutical Indus-
tries Company (EPICO, Egypt). Anhydrous carboxylic acids, tartaric, citric and oxalic acid, 
were purchased from El Nasr, Chemical and Pharmaceutical Company (Egypt). Ethanol 
(95 %) was purchased from El-Gomhoria Company (Egypt). Methanol HPLC grade was 
purchased from Sigma Aldrich (UK). Triethanolamine was purchased from BDH Prolabo 
(UK). Other chemicals were of analytical grade and were used as obtained.
Preparation of clozapine/carboxylic acid co-amorphous dispersions
Solvent evaporation under vacuum was adopted as the method for preparation of co -
-amorphous systems in a modifi cation of the slow solvent evaporation method usually used 
for crystallization (where fast evaporation under vacuum with li le heat is used instead of 
slow evaporation at room temperature) (21). Weighted amounts of clozapine (150 mg) and 
calculated equivalent amounts of anhydrous CAPs, citric, D-tartaric or oxalic acid (chem-
ical structures given in Fig. 1), at the selected molar ratios (Table I), were dissolved in 20 
mL ethanol (95 %) and then placed in a rotary evaporation fl ask. The selected acids had low 
molecular mass and low glass transition temperature and were expected to help amor-
phization of clozapine via lowering of its glass transition temperature. Since polycarbox-
ylic acids undergo intra- and inter-molecular interactions (H-bonding), this could also 
happen with drugs with donor and acceptor nitrogen atoms such as clozapine, especially 
during rapid co-precipitation with one of the acids under vacuum from an alcoholic solu-
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tion. The fl ask contents were then subjected to sonication for 10 min in a water bath sonicator 
(Ultrasonic Cleaner Model 57 H, Ney Instruments Co. Ltd, USA) until all contents were com-
pletely dissolved. The resulting solution was evaporated under vacuum (0.239 MPa) using a 
rotary evaporator (Barloworld Scientifi c Ltd., UK). The water bath temperature was kept at 45 
°C. Upon complete dryness, the collected mass was pulverized and passed through a number 
60 sieve (250 µm apertures), and then kept in a desiccator until further use.
Scanning electron microscopy (SEM)
The morphology of prepared dispersions was examined using scanning electron mi-
croscopy (Analytical Scanning Microscope, JEOL-JSM-6510LA, JEOL, Japan). Few specks 
from each formulation were placed on the carbon stubs and then coated using a gold spu er 
(SPI-Module Spu er Coater, SPI Supplies Inc., USA), followed by microscopical scanning.
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Fig. 1. Chemical structure of clozapine and polycarboxylic acid plasticizers.
Table I. Composition of clozapine-carboxylic acid co-amorphous dispersions
Formulation Clozapine (mg) Citric acid (mg) Tartaric acid (mg)
Oxalic acid
(mg)
Stoichiometric
ratio
Mr 306.80 192.12 150.09 90.03 –
F1 150   94.50 – – 1.0:1.0
F2 150 141.75 – – 1.0:1.5
F3 150 189.00 – – 1.0:2.0
F4 150 –   73.50 – 1.0:1.0
F5 150 – 110.25 – 1.0:1.5
F6 150 – 147 – 1.0:2.0
F7 150 – – 43.50 1.0:1.0
F8 150 – – 65.25 1.0:1.5
F9 150 – – 87.00 1.0:2.0
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Diff erential scanning calorimetry (DSC)
Samples of pure clozapine, CAPs and the prepared co-amorphous dispersion formu-
lations (5 mg each) were individually fi lled into aluminium fl at-bo omed pans and heated 
in a DSC-60 instrument (Shimadzu, Japan) in nitrogen atmosphere. The heating tempera-
ture used for the crystalline components was set between 20 and 300 oC with a heating rate 
10 oC min–1. To accurately detect glass transition (Tg) of the prepared co-amorphous disper-
sions, another heating range was selected (–40 to 300 °C). Comparisons were made with 
amorphous clozapine prepared by melting at 190 °C, followed by quench cooling under 
liquid nitrogen (14).
X-ray powder diff raction (XRPD)
Samples of clozapine powder, CAPs as well as solid dispersion formulations were sub-
ject to X-ray diff raction analysis. A Shimadzu XRD-6000 X-ray powder diff ractometer (Shi-
madzu, Japan) coupled with a standard Cu sealed X-ray tube with voltage, and current (40 
kV and 40 mA), was used to characterize the amorphous or crystalline state of formulations 
(22). Data collection was performed at 2-theta of 5–60° in steps of 0.04 and scanning speed 
of 0.4 per step. Any change in the crystalline pa ern of the prepared co-amorphous disper-
sions compared to those of the parent crystalline components was recorded and evaluated.
Fourier transform infra-red analysis (FTIR)
Small samples (2–3 mg) of clozapine, coformers and prepared dispersions were indi-
vidually mixed with 500 mg of dry potassium bromide. Powder mixtures were compressed 
into discs under a pressure of 68.5–103.4 MPa using a hydrostatic press. The infrared spec-
trum was determined in a scanning range of 400–4000 cm–1 using a Fourier transform 
infra red instrument (Thermo Scientifi c Nicolet 6700, USA).
Drug content evaluation
Samples of the prepared amorphous dispersions equivalent to 5 mg clozapine were 
dissolved in distilled water and adjusted to volume using a standard 50-mL volumetric 
fl ask. Then, 2 mL were taken and diluted to 10 mL with the mobile phase. Drug content 
was then determined using the HPLC system composed of an isocratic pump (Model LC-
10 As, Shimadzu), C18 column (3.9 × 150 mm BondaPack 10 µm, Waters Chromatography, 
USA) and an ultraviolet wavelength detector (Model SpD-10 A, Shimadzu). The mobile 
phase consisted of methanol/water (78:22) with 0.5 %, V/V, triethanolamine. The detection 
wavelength was set at 254 nm and the fl ow rate at 1 mL min–1 (23).
In vitro dissolution studies
Dissolution of clozapine from the prepared co-amorphous dispersions was evaluated 
and compared to that of pure crystalline clozapine. An amount equivalent to 10 mg clo-
zapine from each formulation was compressed into tablets using lactose monohydrate as 
a fi ller. Tablets weighing 100 mg each were compressed using a single punch machine with 
convex 5-mm punch and die set (single punch tablet press, model TDP, Triowin Lab Tech. 
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Co. Ltd., China). The compression step using lactose was necessary to diff erentiate be-
tween formulations due to immediate (fl ash) dissolution of the powder formulations once 
sprinkled into the dissolution medium and to temporarily protect hygroscopic formula-
tions from adherence to the die if compressed alone. The dissolution process was carried 
out using a USP dissolution tester apparatus II (paddle method, SR 8 plus model, Hanson 
Research, USA). The dissolution medium was composed of 500 mL distilled water and the 
paddles rotated at a speed of 50 rpm with water bath temperature kept at 37 ± 0.5 °C. At 
short time intervals (5, 10, 15, 20 and 30 min), samples were withdrawn for analysis and 
replaced with fresh medium.
Solution stability study
Solutions of co-amorphous dispersion formulations containing equivalent amounts 
to 5 mg clozapine dissolved in 50 mL distilled water were prepared and stored at a tem-
perature of 40 °C and 75 % relative humidity for two weeks. This study was performed in 
order to assure that solutions of the prepared dispersions formed homogeneous one phase 
systems probably through H-bonding interactions with improved hydration (i.e., showing 
clear solutions without signs of precipitation of single components). These conditions were 
adjusted using a controlled temperature hot air oven and a saturated salt solution (3). Solu-
tions were investigated for their physical appearance including clarity, separation or pre-
cipitation at the end of the storage period, in addition to re-evaluation of drug content. The 
obtained results were compared with those pertaining to freshly prepared dispersion 
sample solutions.
RESULTS AND DISCUSSION
Morphological characterization
Scanning electron microscopy of the prepared dispersions indicated formation of 
bri le fl ake-like amorphous powders between clozapine and all plasticizing acids at vari-
ous stoichiometric ratios (Fig. 2).
Diff erential scanning calorimetry
The individual DSC thermograms of crystalline clozapine, citric, D-tartaric and ox-
alic acids showed single characteristic endothermic melting peaks at 185, 158, 210 and 194 
°C, respectively (Table II). The thermograms physical mixtures of CZ-citric, CZ-tartaric 
and CZ-oxalic acid ratio at 1:1, also demonstrated separate melting peaks at lower tem-
peratures (157.23, 183.42 and 142.67 °C), respectively, suggesting possible interactions (Ta-
ble II). Thermograms of the co-amorphous dispersions F1–F3 (Fig. 3a) containing citric acid 
at 1, 1.5 and 2 molar ratios, respectively, showed broad peaks with no sharp melting. The 
appearance of single Tgs at 65.21 and 114.01 °C for F2 and F3 (Table II), respectively, also 
suggest formation of co-amorphous phases (24). The prepared amorphous clozapine by 
melting and quench cooling also demonstrated a Tg at 65 °C (Table II), whilst the dispersion 
F1 showed two Tg values at 11 and 68.20 °C suggesting formation of separate amorphous 
components. This result correlates well with the data previously reported for clozapine, 
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Fig. 2. Scanning electron micrographs of solid co-amorphous dispersions of clozapine with: a) citric 
acid F3, b) tartaric acid F4, c) tartaric acid F6 and d) oxalic acid F7.
Table II. Dissolution characteristics of clozapine co-amorphous dispersions and a ributes of solution stability
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Physical 
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Q10
(%)e
Q20
(%)f
Clozapine – 185 (none) 65.0 5.0 100.0   99.0 56.8 67.8
F1 157.2 158 (citric) 11.0/68.2 8.1   75.5   75.0 52.5 77.7
F2 – 158 (citric) 65.2 9.7   55.3 100.0 79.8 92.7
F3 – 158 (citric) 114.0 11.3   50.2   90.9 78.5 85.9
F4 183.4 210 (tartaric) 11.4/69.9 7.4   76.0   82.7 80.6 96.1
F5 – 210 (tartaric) 72.2 8.7   56.5 100.0 71.6 84.7
F6 – 210 (tartaric) 77.7 9.9   55.9   95.6 86.9 96.0
F7 142.7 194 (oxalic) 82.7/115.9 6.4   85.4   96.5 71.0 90.9
F8 – 194 (oxalic) 48.0/112.3 7.2   69.6   93.2 78.0 97.2
F9 – 194 (oxalic) 67.6 7.9   81.9   92.1 74.8 88.2
a Tg1 or Tg1/Tg2
b Weighed amount of dispersion mass equivalent to 5 mg clozapine.
c Percentage clozapine content in fresh samples (n = 3).
d Percentage clozapine remaining in solution a er two weeks of storage.
e, f Percentage clozapine dissolved a er 10 and 20 minutes, respectively.
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which demonstrated various glass transition temperatures (51, 54 and 64° C) in its amor-
phous blends with chitosan (8) and those reported for amorphous citric acid exhibiting a 
glass transition temperature at 11° C (25). The DSC thermograms of F4-F6 (containing D-
tartaric acid at 1, 1.5 and 2 molar ratio, respectively) shown in Fig. 3b, also demonstrated 
broad peaks with complete disappearance of characteristic melting endotherms of parent 
components. The co-amorphous dispersion F4 demonstrated two diff erent Tg values, how-
ever formulation F5 and F6 showed single Tg at 72.23 and 77.73 °C, respectively (Table II). 
The observed single Tgs were quite higher than that of amorphous clozapine (65 °C) which 
indicate formation of highly stable co-amorphous dispersions. The co-amorphous disper-
sions F7 and F8 (containing oxalic acid at 1 and 1.5 molar ratio, respectively) showed simi-
lar broad thermograms (Fig. 3c) to those observed with CZ-citric and CZ-tartaric acid 
dispersions. Each of F7 and F8 exhibited two Tg temperatures representing formation of 
two separate amorphous phases, whilst F9 showed single Tg at 67.58 °C (Table II) indicating 
homogenous co-amorphous system. The above results indicated that the interaction be-
tween clozapine and CAPS is possible in all proportions. However, possibility of forma-
tion of homogenous co-amorphous dispersions with single Tg values were only observed 
at specifi c molar ratios.
Fig. 3. DSC curves for clozapine co-amorphous dispersions with: a) citric acid (F1–F3), b) tartaric acid 
(F4–F6) and c) oxalic acid (F7–F9). Arrows refer to Tg points.
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X-ray powder diff raction
X-ray diff raction pa erns of clozapine (Fig. 4a) demonstrated characteristic intense 
peaks between 2-theta 10, 17, 19.5, 21 23.7, 25 and 30°, indicating a crystalline structure. 
These results are in good agreement with what was reported for clozapine in the literature 
(6). The XRD pa ern for citric acid also showed multiple sharp characteristic peaks at 
2-theta of 13, 14, 19, 25, 28, 32, 34, 36, 38, 42 and 58°. The XRD spectra of co-amorphous 
dispersions F1, F2 and F3 demonstrated disappearance of the characteristic peaks of both 
citric acid and clozapine and appearance of the characteristic amorphous halo. The appear-
ance of a characteristic amorphous halo in all the co-amorphous dispersions, along with 
DSC data, strongly suggest that amorphous systems were obtained through H-bonding 
interactions between the drug and the plasticizing acid (26). Formulation F3 showed a 
Fig. 4. XRPD pa erns for: a) clozapine, citric acid and its amorphous solid dispersions F1–F3, b) clo-
zapine, tartaric acid and its co-amorphous dispersions (F4–F6), c) clozapine, oxalic acid and its co-
amorphous dispersions (F7–F9).
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single sharp refl ection at 2-theta of 28o, which indicates the presence of the remaining 
crystalline components and separation of phases (amorphous and crystalline).
The XRPD pa erns for D-tartaric acid and its co-amorphous dispersions with clozap-
ine are shown in Fig. 4b and demonstrated two sharp peaks characteristic of the acid at 
2-theta of 19 and 22o with other multiple peaks 30–45°. The XRD pa erns observed for 
formulations F4, F5 and F6 were highly a enuated compared to those of clozapine and 
D-tartaric acid and the characteristic amorphous halo was also observed. Formulation F5 
showed the lowest a enuation and had a new single short refl ection at 2-theta of 28°. This 
la er refl ection is similar to that of F3 and both suggest incomplete interactions between 
clozapine and the acid leaving unreacted crystalline components. Oxalic acid XRD pat-
terns shown in Fig. 4c demonstrated characteristic peaks at 2-theta of 22, 23, 28 and 42°. The 
co-amorphous dispersions F7, F8 and F9 showed the disappearance of characteristic peaks 
and appearance of a broad short halo at 2-theta of 20° similar to those found with citric and 
tartaric acid dispersions. From the observations of broad DSC thermograms with no sharp 
melting and the amorphous halo in XRPD pa erns, it becomes obvious that amorphous 
dispersions rather than crystalline structures were formed (27). From these dispersion 
systems, co-amorphous homogenous phases were observed in F2, F5, F6 and F9. This can 
be also supported by investigation of the infrared spectra of parent components compared 
to the prepared dispersions.
IR-spectral analysis
The results of FTIR spectra for clozapine (Fig. 5a) indicated a characteristic peak at 
3000–3300 cm–1, which represents the free N-H stretching of the diazepine ring and at 
2921, 2789 and 2791 cm–1, representing aliphatic C-H stretching as reported in the literature 
(7). The FTIR spectra of pure citric acid indicated a characteristic peak at 1705 cm−1, which 
was a ributed to the C=O stretching vibration in carboxyl groups. Formulations F1, F2 and 
F3 showed shortened peaks of clozapine (C-H stretching and C=N stretching) and a broad-
ened shallow peak of N-H stretching shi ing to 3396 cm–1 instead of 3282 cm–1. The IR 
spectra of D-tartaric acid shown in Fig. 5b demonstrated the characteristic carbonyl group 
C=O stretching of tartaric acid at 1725 cm–1 and a broad peak between 3200–3400 indicating 
O-H stretching. In formulations F4–F6, the characteristic peaks of clozapine at 3000–3300 
cm–1 (N-H stretching) overlapped with those of tartaric acid (O-H stretching), forming a 
broad band in this region with short frequencies, which may suggest H-bonding interac-
tion. Similar spectral changes were observed for CZ-oxalic acid co-amorphous dispersions 
(Fig. 5c). These results along with previous DSC and XRPD data, suggest interaction be-
tween clozapine and the carboxylic acids, most probably through H-bonding.
Drug content
The amount of clozapine incorporated in the co-amorphous dispersion formulations 
was determined a er HPLC analysis of samples and the results showed that the maximum 
amount of clozapine (85 % of actually weighed amount in formula) was found in F7 while 
the lowest amount was found into F3 (50 %). This la er observation with F3 was expected 
from a previous observation of incomplete interaction of CZ and citric acid at a 1:2 molar 
ratio with the remaining crystallinity (XRPD data in Fig. 4a). The content showed interme-
diate values for formulation F9 (81 %). The results indicated diff erent tendencies or affi  ni-
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Fig. 5. IR spectra of clozapine co-amorphous dispersions with: a) citric acid, b) D-tartaric acid, and c) 
oxalic acid.
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ties between clozapine and each of the plasticizing acids towards H-bonding (as demon-
strated by the diff erences in percentage of dissolution), being the highest for oxalic and the 
lowest for citric and tartaric acid. It also demonstrated that there were optimum ratios of 
drug-to-plasticizing acid, where complete interaction would predominantly result in a 
high-drug content amorphous dispersion. This ratio was 1:1 in case of citric and tartaric 
acids, 1:1 and 1:2 in case of oxalic acid.
In vitro dissolution studies
The results of percentage dissolution studies (Fig. 6) performed for the prepared co-
amorphous dispersion formulations indicated higher percentage dissolution of clozapine 
from compressed tablets (n = 3) containing a co-amorphous dispersion compared to those 
containing the parent crystalline pure drug. Formulation F6 containing CZ-tartaric acid in 
a 1:2 ratio demonstrated the highest release (86.9 % in 10 min). Formulations F2, F4, F6, F7 
and F8 released more than 90 % of clozapine within the fi rst 20 min (see Table II). Formula-
tions F3, F5 and F9 demonstrated intermediate release values and similar profi les. These 
results indicate that amorphization of clozapine using CAPs led to the formation of highly 
dissolving dispersions that can be formulated into instantly dissolving dosage forms such 
as sublingual and orodispersible tablets.
Solution stability
The solution stability data suggest that the plasticizing acids had diff erent ability to 
form stable solutions from plasticized co-amorphous dispersions (i.e., the ratio and type of 
the acid directly aff ected the extent of formed amorphous clozapine). Higher stability 
could be obtained from tartaric and citric acid followed by oxalic acid. Separation of very 
fi ne particles was exhibited by F8 and, to a lesser extent, by F7. This behavior might be at-
tributed to diff erent solubility of the two separate amorphous components in the mixture 
Fig. 6. Dissolution profi les of clozapine from diff erent co-amorphous dispersions (F1–F9) compared 
to pure clozapine.
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(93.2 % in dissolved state for F7 and 96.5 % in case of F8). Other solutions showed no signs 
of visual separation or precipitation of particles. HPLC analyses of stored solutions indi-
cated that the smallest percentage of detected drug in solution was observed for formula-
tion F1, whilst the maximum level was demonstrated by F2 (CZ-citric 1:1.5) and F5 (CZ-
tartaric 1:1.5), which showed 100 % of the drug remaining in solution. Formulations F3, F6, 
F7, F8 and F9 showed more than 90 % of the drug remaining at the end of the storage pe-
riod of two weeks at 40 °C and 75 % RH (see Table II).
CONCLUSIONS
The above fi ndings indicate that rapid solvent evaporation under vacuum is an excel-
lent method for preparation of clozapine-CAPs co-amorphous dispersions. Carboxylic 
acids enabled formation of new phases via H-bonding interactions and lowering of the 
drug glass transition. This facilitated conversion of crystalline clozapine to the more fl ex-
ible co-amorphous mixture characterized by maximum drug solubility and percentage 
dissolution. Therefore, co-amorphous dispersions can be considered a valuable solution 
for drugs having poor water solubility. Clozapine co-amorphous dispersions formed be-
tween clozapine and tartaric acid showed the highest percentage dissolution, followed by 
oxalic and citric acid. However, citric and tartaric acid demonstrated the highest chances 
for stable co-amorphous dispersions with clozapine at a 1:1.5 molar ratio. Based on these 
fi ndings, selected carboxylic acids, at specifi c molar ratios, can be used eff ectively to for-
mulate stable co-amorphous dispersions with high dissolution properties from poorly 
soluble crystalline drugs such as clozapine.
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